Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Why isn't Pfizer's COVID-19 vaccine OK'd yet? White House calls in FDA chief Hahn to explain: Axios
Bipartisan COVID-19 package includes $100B for providers, short-term liability protections
Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study
Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape
Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies
Healthcare roundup: AMA, AHA, ANA back 'science-based' vaccine process
Biopharma roundup: Regeneron taps Penn, Jim Wilson for antibody nasal spray; Trump's pandemic adviser Atlas hits the exit
Trinity Health posts $112M in Q3 earnings as system rebounds from COVID-19 drop
Cleveland Clinic posts increased Q3 income, but profits still down for first 9 months of 2020
AMGA urges CMS to continue to allow for telephonic visits in Medicare Advantage

Featured Story

Why isn't Pfizer's COVID-19 vaccine OK'd yet? White House calls in FDA chief Hahn to explain: Axios

By Eric Sagonowsky

Throughout the pandemic, White House officials have twisted arms at the FDA—and sometimes succeeded. Now, in the final months of the Trump administration, agency chief Stephen Hahn, M.D., has been summoned to explain why FDA hasn't authorized Pfizer's vaccine yet, Axios reports.

Bipartisan COVID-19 package includes $100B for providers, short-term liability protections

By Robert King

Bipartisan lawmakers introduced a COVID-19 relief package that includes $100 billion for providers and short-term liability protections from lawsuits related to the pandemic.

Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study

By Angus Liu

Even as the FDA has already approved or authorized several COVID-19 drugs, there's still plenty of room for better therapies for a broad variety of patients. Now, three pharma companies have decided to assess drugs from their own portfolios in a new clinical trial among hospitalized patients.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID-19 antibody cocktail using AAV tech in the hope of curbing infection via a nasal spray.

Healthcare roundup: AMA, AHA, ANA back 'science-based' vaccine process

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: Regeneron taps Penn, Jim Wilson for antibody nasal spray; Trump's pandemic adviser Atlas hits the exit

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

Regeneron tapped Jim Wilson and the University of Pennsylvania to help deliver its antibody cocktail intranasally. Amgen, Takeda and UCB launched an adaptive trial to see whether a trio of drugs could curb inflammatory responses in COVID patients. Trump's pandemic advisor Scott Atlas hit the exit. And Europe will review Pfizer's shot by Dec. 29.

COVID-19 Tracker

Featured Story

Why isn't Pfizer's COVID-19 vaccine OK'd yet? White House calls in FDA chief Hahn to explain: Axios

Top Stories

Bipartisan COVID-19 package includes $100B for providers, short-term liability protections

Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study

Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape

Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies

Healthcare roundup: AMA, AHA, ANA back 'science-based' vaccine process

Biopharma roundup: Regeneron taps Penn, Jim Wilson for antibody nasal spray; Trump's pandemic adviser Atlas hits the exit

Trinity Health posts $112M in Q3 earnings as system rebounds from COVID-19 drop

Cleveland Clinic posts increased Q3 income, but profits still down for first 9 months of 2020

AMGA urges CMS to continue to allow for telephonic visits in Medicare Advantage